The vitreomacular interface in diabetic retinopathy

Daniel Agarwal, Rachel Gelman, Claudia Prospero Ponce, William Stevenson, John B Christoforidis

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Diabetic retinopathy (DR) is a leading health concern and a major cause of blindness. DR can be complicated by scar tissue formation, macular edema, and tractional retinal detachment. Optical coherence tomography has found that patients with DR often have diffuse retinal thickening, cystoid macular edema, posterior hyaloid traction, and tractional retinal detachment. Newer imaging techniques can even detect fine tangential folds and serous macular detachment. The interplay of the vitreous and the retina in the progression of DR involves multiple chemokine and other regulatory factors including VEGF. Understanding the cells infiltrating pathologic membranes at the vitreomacular interface has opened up the possibility of new targets for pharmacotherapy. Vitrectomies for DR remain a vital tool to help relieve tension on the macula by removing membranes, improving edema absorption, and eliminating the scaffold for new membrane formation. Newer treatments such as triamcinolone acetonide and VEGF inhibitors have become essential as a rapid way to control DR at the vitreomacular interface, improve macular edema, and reduce retinal neovascularization. These treatments alone, and in conjunction with PRP, help to prevent worsening of the VMI in patients with DR.

Original languageEnglish (US)
Article number392983
JournalJournal of Ophthalmology
Volume2015
DOIs
StatePublished - 2015

Fingerprint

Diabetic Retinopathy
Macular Edema
Retinal Detachment
Vascular Endothelial Growth Factor A
Membranes
Retinal Neovascularization
Triamcinolone Acetonide
Vitrectomy
Optical Coherence Tomography
Traction
Blindness
Chemokines
Cicatrix
Retina
Edema
Drug Therapy
Health
Therapeutics

ASJC Scopus subject areas

  • Ophthalmology

Cite this

The vitreomacular interface in diabetic retinopathy. / Agarwal, Daniel; Gelman, Rachel; Prospero Ponce, Claudia; Stevenson, William; Christoforidis, John B.

In: Journal of Ophthalmology, Vol. 2015, 392983, 2015.

Research output: Contribution to journalArticle

Agarwal, Daniel ; Gelman, Rachel ; Prospero Ponce, Claudia ; Stevenson, William ; Christoforidis, John B. / The vitreomacular interface in diabetic retinopathy. In: Journal of Ophthalmology. 2015 ; Vol. 2015.
@article{ac468a84c02d4a4d9ee17caacc794014,
title = "The vitreomacular interface in diabetic retinopathy",
abstract = "Diabetic retinopathy (DR) is a leading health concern and a major cause of blindness. DR can be complicated by scar tissue formation, macular edema, and tractional retinal detachment. Optical coherence tomography has found that patients with DR often have diffuse retinal thickening, cystoid macular edema, posterior hyaloid traction, and tractional retinal detachment. Newer imaging techniques can even detect fine tangential folds and serous macular detachment. The interplay of the vitreous and the retina in the progression of DR involves multiple chemokine and other regulatory factors including VEGF. Understanding the cells infiltrating pathologic membranes at the vitreomacular interface has opened up the possibility of new targets for pharmacotherapy. Vitrectomies for DR remain a vital tool to help relieve tension on the macula by removing membranes, improving edema absorption, and eliminating the scaffold for new membrane formation. Newer treatments such as triamcinolone acetonide and VEGF inhibitors have become essential as a rapid way to control DR at the vitreomacular interface, improve macular edema, and reduce retinal neovascularization. These treatments alone, and in conjunction with PRP, help to prevent worsening of the VMI in patients with DR.",
author = "Daniel Agarwal and Rachel Gelman and {Prospero Ponce}, Claudia and William Stevenson and Christoforidis, {John B}",
year = "2015",
doi = "10.1155/2015/392983",
language = "English (US)",
volume = "2015",
journal = "Journal of Ophthalmology",
issn = "2090-004X",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - The vitreomacular interface in diabetic retinopathy

AU - Agarwal, Daniel

AU - Gelman, Rachel

AU - Prospero Ponce, Claudia

AU - Stevenson, William

AU - Christoforidis, John B

PY - 2015

Y1 - 2015

N2 - Diabetic retinopathy (DR) is a leading health concern and a major cause of blindness. DR can be complicated by scar tissue formation, macular edema, and tractional retinal detachment. Optical coherence tomography has found that patients with DR often have diffuse retinal thickening, cystoid macular edema, posterior hyaloid traction, and tractional retinal detachment. Newer imaging techniques can even detect fine tangential folds and serous macular detachment. The interplay of the vitreous and the retina in the progression of DR involves multiple chemokine and other regulatory factors including VEGF. Understanding the cells infiltrating pathologic membranes at the vitreomacular interface has opened up the possibility of new targets for pharmacotherapy. Vitrectomies for DR remain a vital tool to help relieve tension on the macula by removing membranes, improving edema absorption, and eliminating the scaffold for new membrane formation. Newer treatments such as triamcinolone acetonide and VEGF inhibitors have become essential as a rapid way to control DR at the vitreomacular interface, improve macular edema, and reduce retinal neovascularization. These treatments alone, and in conjunction with PRP, help to prevent worsening of the VMI in patients with DR.

AB - Diabetic retinopathy (DR) is a leading health concern and a major cause of blindness. DR can be complicated by scar tissue formation, macular edema, and tractional retinal detachment. Optical coherence tomography has found that patients with DR often have diffuse retinal thickening, cystoid macular edema, posterior hyaloid traction, and tractional retinal detachment. Newer imaging techniques can even detect fine tangential folds and serous macular detachment. The interplay of the vitreous and the retina in the progression of DR involves multiple chemokine and other regulatory factors including VEGF. Understanding the cells infiltrating pathologic membranes at the vitreomacular interface has opened up the possibility of new targets for pharmacotherapy. Vitrectomies for DR remain a vital tool to help relieve tension on the macula by removing membranes, improving edema absorption, and eliminating the scaffold for new membrane formation. Newer treatments such as triamcinolone acetonide and VEGF inhibitors have become essential as a rapid way to control DR at the vitreomacular interface, improve macular edema, and reduce retinal neovascularization. These treatments alone, and in conjunction with PRP, help to prevent worsening of the VMI in patients with DR.

UR - http://www.scopus.com/inward/record.url?scp=84941687113&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941687113&partnerID=8YFLogxK

U2 - 10.1155/2015/392983

DO - 10.1155/2015/392983

M3 - Article

VL - 2015

JO - Journal of Ophthalmology

JF - Journal of Ophthalmology

SN - 2090-004X

M1 - 392983

ER -